T2 Biosystems to Participate in Two Upcoming Investor Conferences
September 10 2018 - 7:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development and commercialization of innovative medical diagnostic
products for critical unmet needs in healthcare, announced today
that John McDonough, president and chief executive officer, is
scheduled to participate in two upcoming investor conferences.
The first conference is the Janney Healthcare Conference 2018,
which is being held September 17-18 in New York City. This
conference will allow institutional investors to meet with the
Company but does not include a formal webcast presentation. The
Company will be available to meet with investors on September
17.
The second conference is the Cantor Global Healthcare
Conference, which is being held October 1-3 in New York City. The
Company is scheduled to present at the Cantor conference
on Tuesday, October 2, 2018 at 8:35 a.m. ET and
will be available for one-on-one meetings during the conference.
The presentation will be webcast live and available for replay and
may be accessed by visiting the Investors/Events &
Presentations section of the Company’s website
at www.t2biosystems.com. A replay of the
webcast will be available shortly after the conclusion of the
presentation and will be archived on the Company's website for 90
days following the presentation.
About T2 Biosystems:T2 Biosystems, an emerging
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel and are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease. For more
information, please visit www.t2biosystems.com.
Media Contact: Gina Kent, Vault
Communicationsgkent@vaultcommunications.com610-455-2763
Investor Contact: Matthew Clawson, W2O
Groupmclawson@w2ogroup.com949-370-8500
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024